Osaka

OSAKA, Japan and LONDON, October 21, 2011 - European Medicines Agency recognizes that Takeda's pioglitazone-containing medicines remain a valid treatment option for appropriate type 2 diabetes patients Takeda Pharmaceutical Company Limited ("Takeda") announced today that at the request of the European Commission (EC), the European Medicines Agency (EMA)'s Committee for Medical Products for Human Use (CHMP) has clarified the label changes for pioglitazone-containing medicines recommended in July of this year.

OSAKA, Japan, September 30, 2011 - Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced it has completed its acquisition of Nycomed A/S ("Nycomed") for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day.

OSAKA, Japan and CAMBRIDGE, Massachusetts, June 27, 2011 - Takeda Pharmaceutical Company Limited (TSE:4502) together with its wholly-owned subsidiary Millennium: The Takeda Oncology Company, today announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for ADCETRIS™ (brentuximab vedotin) for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

OSAKA, Japan, and ZURICH, May 19, 2011 - Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Nycomed A/S ("Nycomed") jointly announced today that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for 9.6 billion Euro on a cash-free, debt-free basis.

OSAKA, Japan, April 1, 2011 - Takeda Pharmaceutical Company Limited ("Takeda") announced that effective April 1, Trevor Smith, currently Vice President, International Strategy, will assume the role of Chief Executive Officer of Takeda Pharmaceuticals Europe Limited ("TPEU"), its wholly owned subsidiary for oversight of pan-European sales and marketing.